细胞减灭术和腹腔内热灌注化疗在结直肠癌腹膜转移的应用研究进展  

The application value and prospect of cell inactivation and intraperitoneal thermal perfusion chemotherapy in patient with colorectal cancer with peritoneal metastasis

作　　者：黄海涛 王振军[1] HUANG Haitao;WANG Zhenjun(Department of General Surgery,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院普外科

出　　处：《临床外科杂志》2019年第11期1011-1013,共3页Journal of Clinical Surgery

摘　　要：腹膜是结直肠癌第二常见的转移部位,预后差,无手术治疗的价值,临床多采取姑息性治疗。随着外科技术、精确控温的腹腔热灌注化疗以及多学科综合治疗的发展,对结直肠癌腹膜转移的认识和治疗策略发生了很大变化,新的化疗药物和靶向生物制剂的引入改善了转移性结直肠癌病人的预后。细胞减灭术(CRS)+腹腔热灌注化疗(HIPEC)联合全身治疗是目前标准疗法,可延长结直肠癌腹膜转移病人的生存期。本文对CRS联合HIPEC在结直肠癌腹膜转移中的应用价值和研究进展进行综述。Peritoneal metastasis is very common in patients with advanced colorectal cancer and is the second most common site of metastasis in colorectal cancer.Traditionally,it is considered to be poor in prognosis and has no value of surgical treatment.With the progress of surgical techniques,precision temperature controlled intraperitoneal perfusion chemotherapy and multidisciplinary comprehensive treatment,the recognition and treatment strategy of peritoneal metastasis of colorectal cancer has changed greatly.The introduction of new chemotherapy drugs and targeted biological agents has improved the prognosis of patients with metastatic colorectal cancer.It is worth noting that the combination of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) with systemic therapy is the current standard therapy,which effectively extends the survival period of patients with colorectal cancer with peritoneal metastasis.This review focused on the current application value and research progress of CRS and HIPEC in peritoneal metastasis of colorectal cancer.

关 键 词：结直肠癌 腹膜转移 细胞减灭术 腹腔内热灌注化疗 

分 类 号：R73[医药卫生—肿瘤]